Immunization with V987H-stabilized Spike glycoprotein protects K18-hACE2 mice and golden Syrian hamsters upon SARS-CoV-2 infection.
Journal
Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555
Informations de publication
Date de publication:
21 Mar 2024
21 Mar 2024
Historique:
received:
21
04
2023
accepted:
27
02
2024
medline:
22
3
2024
pubmed:
22
3
2024
entrez:
22
3
2024
Statut:
epublish
Résumé
Safe and effective severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines are crucial to fight against the coronavirus disease 2019 pandemic. Most vaccines are based on a mutated version of the Spike glycoprotein [K986P/V987P (S-2P)] with improved stability, yield and immunogenicity. However, S-2P is still produced at low levels. Here, we describe the V987H mutation that increases by two-fold the production of the recombinant Spike and the exposure of the receptor binding domain (RBD). S-V987H immunogenicity is similar to S-2P in mice and golden Syrian hamsters (GSH), and superior to a monomeric RBD. S-V987H immunization confer full protection against severe disease in K18-hACE2 mice and GSH upon SARS-CoV-2 challenge (D614G or B.1.351 variants). Furthermore, S-V987H immunized K18-hACE2 mice show a faster tissue viral clearance than RBD- or S-2P-vaccinated animals challenged with D614G, B.1.351 or Omicron BQ1.1 variants. Thus, S-V987H protein might be considered for future SARS-CoV-2 vaccines development.
Identifiants
pubmed: 38514609
doi: 10.1038/s41467-024-46714-w
pii: 10.1038/s41467-024-46714-w
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2349Subventions
Organisme : Generalitat de Catalunya (Government of Catalonia)
ID : SLD0015
Organisme : Generalitat de Catalunya (Government of Catalonia)
ID : 2020 FI_B_0742
Organisme : Generalitat de Catalunya (Government of Catalonia)
ID : 2020FI_B2_00138
Organisme : Generalitat de Catalunya (Government of Catalonia)
ID : 2022 FI_B_00698
Organisme : Generalitat de Catalunya (Government of Catalonia)
ID : SLD0016
Organisme : Generalitat de Catalunya (Government of Catalonia)
ID : 2021SGR00452
Organisme : Ministry of Economy and Competitiveness | Instituto de Salud Carlos III (Institute of Health Carlos III)
ID : PI18/01332
Organisme : Ministry of Economy and Competitiveness | Instituto de Salud Carlos III (Institute of Health Carlos III)
ID : PI17/01518
Organisme : Ministry of Economy and Competitiveness | Agencia Estatal de Investigación (Spanish Agencia Estatal de Investigación)
ID : PID2020-117145RB-I00
Informations de copyright
© 2024. The Author(s).
Références
Wu, F. et al. A new coronavirus associated with human respiratory disease in China. Nature 579, 265–269 (2020).
pubmed: 32015508
pmcid: 7094943
doi: 10.1038/s41586-020-2008-3
Zhu, N. et al. A novel coronavirus from patients with pneumonia in China, 2019. N. Engl. J. Med. 382, 727–733 (2020).
pubmed: 31978945
pmcid: 7092803
doi: 10.1056/NEJMoa2001017
Krammer, F. SARS-CoV-2 vaccines in development. Nature 586, 516–527 (2020).
pubmed: 32967006
doi: 10.1038/s41586-020-2798-3
Premkumar, L. et al. The receptor-binding domain of the viral spike protein is an immunodominant and highly specific target of antibodies in SARS-CoV-2 patients. Sci. Immunol. 5, 1–10 (2020).
doi: 10.1126/sciimmunol.abc8413
Carrillo, J. et al. Humoral immune responses and neutralizing antibodies against SARS-CoV-2; implications in pathogenesis and protective immunity. Biochem. Biophys. Res. Commun. 538, 187–191 (2021).
pubmed: 33187644
doi: 10.1016/j.bbrc.2020.10.108
Yong, C. Y., Ong, H. K., Yeap, S. K., Ho, K. L. & Tan, W. S. Recent advances in the vaccine development against middle east respiratory syndrome-coronavirus. Front. Microbiol. 10, 1–18 (2019).
doi: 10.3389/fmicb.2019.01781
Zhao, J. et al. COVID-19: coronavirus vaccine development updates. Front. Immunol. 11, 1–19 (2020).
doi: 10.3389/fimmu.2020.602256
Walls, A. C. et al. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell 181, 281–292.e6 (2020).
pubmed: 32155444
pmcid: 7102599
doi: 10.1016/j.cell.2020.02.058
Hoffmann, M. et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 181, 271–280.e8 (2020).
pubmed: 32142651
pmcid: 7102627
doi: 10.1016/j.cell.2020.02.052
Cai, Y. et al. Distinct conformational states of SARS-CoV-2 spike protein. Science 369, 1586–1592 (2020).
pubmed: 32694201
doi: 10.1126/science.abd4251
Graham, B. S., Gilman, M. S. A. & McLellan, J. S. Structure-based vaccine antigen design. Annu. Rev. Med. 70, 91–104 (2019).
pubmed: 30691364
pmcid: 6936610
doi: 10.1146/annurev-med-121217-094234
Pallesen, J. et al. Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen. Proc. Natl Acad. Sci. USA 114, E7348–E7357 (2017).
pubmed: 28807998
pmcid: 5584442
doi: 10.1073/pnas.1707304114
Wrapp, D. et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science 367, 1260–1263 (2020).
pubmed: 32075877
pmcid: 7164637
doi: 10.1126/science.abb2507
Corbett, K. S. et al. SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness. Nature 586, 567–571 (2020).
pubmed: 32756549
pmcid: 7581537
doi: 10.1038/s41586-020-2622-0
Lu, S. Heterologous prime-boost vaccination. Curr. Opin. Immunol. 21, 346–351 (2009).
pubmed: 19500964
pmcid: 3743086
doi: 10.1016/j.coi.2009.05.016
Vidal, E. et al. Chronological brain lesions after SARS-CoV-2 infection in hACE2-transgenic mice. Vet. Pathol. 59, 613–626 (2022).
pubmed: 34955064
doi: 10.1177/03009858211066841
Sia, S. F. et al. Pathogenesis and transmission of SARS-CoV-2 in golden hamsters. Nature 583, 834–838 (2020).
pubmed: 32408338
pmcid: 7394720
doi: 10.1038/s41586-020-2342-5
Brustolin, M. et al. Protection against reinfection with D614- or G614-SARS-CoV-2 isolates in golden Syrian hamster. Emerg. Microbes Infect. 12, 1–36 (2021).
Muñoz-Fontela, C. et al. Animal models for COVID-19. Nature 586, 509–515 (2020).
pubmed: 32967005
pmcid: 8136862
doi: 10.1038/s41586-020-2787-6
Salehi-Vaziri, M. et al. The ins and outs of SARS-CoV-2 variants of concern (VOCs). Arch. Virol. 167, 327–344 (2022).
pubmed: 35089389
pmcid: 8795292
doi: 10.1007/s00705-022-05365-2
Pradenas, E. et al. Clinical course impacts early kinetics,magnitude, and amplitude of SARS-CoV-2 neutralizing antibodies beyond 1 year after infection. Cell Rep. Med. 3, 100523 (2022).
pubmed: 35233547
pmcid: 8784437
doi: 10.1016/j.xcrm.2022.100523
Tarrés-Freixas, F. et al. Heterogeneous infectivity and pathogenesis of SARS-CoV-2 variants beta, delta and omicron in transgenic K18-hACE2 and wildtype mice. Front. Microbiol. 13, 840757 (2022).
Kim, E. H. et al. Squalene emulsion-based vaccine adjuvants stimulate CD8 T cell, but not antibody responses, through a RIPK3-dependent pathway. Elife 9, 1–27 (2020).
doi: 10.7554/eLife.52687
Case, J. B. et al. Characterization of the SARS-CoV-2 BA.5.5 and BQ.1.1 Omicron variants in mice and hamsters. J. Virol. 97, e0062823 (2023).
pubmed: 37676002
doi: 10.1128/jvi.00628-23
Grifoni, A. et al. Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals. Cell 181, 1489–1501.e15 (2020).
pubmed: 32473127
pmcid: 7237901
doi: 10.1016/j.cell.2020.05.015
Xiong, X. et al. A thermostable, closed SARS-CoV-2 spike protein trimer. Nat. Struct. Mol. Biol. 27, 934–941 (2020).
pubmed: 32737467
pmcid: 7116388
doi: 10.1038/s41594-020-0478-5
McCray, P. B. et al. Lethal infection of K18-hACE2 mice infected with severe acute respiratory syndrome coronavirus. J. Virol. 81, 813–821 (2007).
pubmed: 17079315
doi: 10.1128/JVI.02012-06
Vaccari, M. et al. Adjuvant-dependent innate and adaptive immune signatures of risk of SIVmac251 acquisition. Nat. Med. 22, 762–770 (2016).
pubmed: 27239761
pmcid: 5916782
doi: 10.1038/nm.4105
Costello, S. M. et al. The SARS-CoV-2 spike reversibly samples an open-trimer conformation exposing novel epitopes. Nat. Struct. Mol. Biol. 29, 229–238 (2022).
pubmed: 35236990
pmcid: 9007726
doi: 10.1038/s41594-022-00735-5
Hsieh, C.-L. et al. Structure-based design of prefusion-stabilized SARS-CoV-2 spikes. Science 369, 1501–1505 (2020).
pubmed: 32703906
doi: 10.1126/science.abd0826
Sun, W. et al. A Newcastle disease virus expressing a stabilized spike protein of SARS-CoV-2 induces protective immune responses. Nat. Commun. 12, 6197 (2021).
pubmed: 34707161
pmcid: 8551302
doi: 10.1038/s41467-021-26499-y
Juraszek, J. et al. Stabilizing the closed SARS-CoV-2 spike trimer. Nat. Commun. 12, 1–8 (2021).
doi: 10.1038/s41467-020-20321-x
Riley, T. P. et al. Enhancing the prefusion conformational stability of SARS-CoV-2 spike protein through structure-guided design. Front. Immunol. 12, 660198 (2021).
pubmed: 33968063
pmcid: 8100506
doi: 10.3389/fimmu.2021.660198
Tan, T. J. C. et al. High-throughput identification of prefusion-stabilizing mutations in SARS-CoV-2 spike. Nat. Commun. 14, 2003 (2023).
pubmed: 37037866
pmcid: 10086000
doi: 10.1038/s41467-023-37786-1
Kalnin, K. V. et al. Immunogenicity and efficacy of mRNA COVID-19 vaccine MRT5500 in preclinical animal models. NPJ Vaccines 6, 61 (2021).
pubmed: 33875658
pmcid: 8055913
doi: 10.1038/s41541-021-00324-5
Lu, M. et al. SARS-CoV-2 prefusion spike protein stabilized by six rather than two prolines is more potent for inducing antibodies that neutralize viral variants of concern. Proc. Natl Acad. Sci. 119, e2110105119 (2022).
pubmed: 35994646
pmcid: 9436349
doi: 10.1073/pnas.2110105119
Waterhouse, A. et al. SWISS-MODEL: homology modelling of protein structures and complexes. Nucleic Acids Res. 46, W296–W303 (2018).
pubmed: 29788355
pmcid: 6030848
doi: 10.1093/nar/gky427
Schymkowitz, J. et al. The FoldX web server: an online force field. Nucleic Acids Res. 33, W382–W388 (2005).
pubmed: 15980494
pmcid: 1160148
doi: 10.1093/nar/gki387
Perez-Zsolt, D. et al. SARS-CoV-2 interaction with Siglec-1 mediates trans-infection by dendritic cells. Cell Mol. Immunol. 18, 2676–2678 (2021).
pubmed: 34782760
pmcid: 8591443
doi: 10.1038/s41423-021-00794-6
Rodon, J. et al. Identification of plitidepsin as potent inhibitor of SARS-CoV-2-induced cytopathic effect after a drug repurposing screen. Front. Pharmacol. 12, 1–12 (2021).
doi: 10.3389/fphar.2021.646676
Kamala, T. Hock immunization: a humane alternative to mouse footpad injections. J. Immunol. Methods 328, 204–214 (2007).
pubmed: 17804011
pmcid: 2464360
doi: 10.1016/j.jim.2007.08.004
Pradenas, E. et al. Stable neutralizing antibody levels 6 months after mild and severe COVID-19 episodes. Medicines 2, 313–320.e4 (2021).
Connor, R. I., Chen, B. K., Choe, S. & Landau, N. R. Vpr is required for efficient replication of human immunodeficiency virus type-1 in mononuclear phagocytes. Virology 206, 935–944 (1995).
pubmed: 7531918
doi: 10.1006/viro.1995.1016
Trinité, B. et al. SARS-CoV-2 infection elicits a rapid neutralizing antibody response that correlates with disease severity. Sci. Rep. 11, 2608 (2021).
pubmed: 33510275
pmcid: 7843981
doi: 10.1038/s41598-021-81862-9
Wölfel, R. et al. Virological assessment of hospitalized patients with COVID-2019. Nature 581, 465–469 (2020).
pubmed: 32235945
doi: 10.1038/s41586-020-2196-x
Corman, V. M. et al. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. Eurosurveillance 25, 2000045 (2020).
pubmed: 31992387
pmcid: 6988269
doi: 10.2807/1560-7917.ES.2020.25.3.2000045